Fundraising FoxSynaffix
3 known investors
Find your way into Synaffix
Sign up to see every warm intro you have to Synaffix
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Synaffix team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Synaffix develops antibody-drug conjugate (ADC) technology, providing linker-payload platforms that attach small-molecule, peptide, and protein-based payloads to antibodies for use in targeted cancer therapies. The company has been integrated into Lonza's Advanced Synthesis business platform.
Investors · 3
Funding
SEC filings, press & company announcements- Undisclosed amountSeries AFeb 2014Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does Synaffix do?
- Synaffix develops antibody-drug conjugate (ADC) technology, providing linker-payload platforms that attach small-molecule, peptide, and protein-based payloads to antibodies for use in targeted cancer therapies. The company has been integrated into Lonza's Advanced Synthesis business platform.
- Who are Synaffix's investors?
- Synaffix's investors include BioGeneration Ventures, BOM, M Ventures.